Article

Investors, drug/device developers share facts

Pittsburgh—Senior executives from some 50 biotechnology, pharmaceutical, and device firms examined the potential for combination drug/device therapies in a weekend conference showcasing the most promising advances.

Pittsburgh-Senior executives from some 50 biotechnology, pharmaceutical, and device firms examined the potential for combination drug/device therapies in a weekend conference showcasing the most promising advances.

The meeting, sponsored by AdvaMed, BIO, MedTech Insight, The Pittsburgh Life Sciences Greenhouse, and Windhover Information, explored the potentially "explosive" growth predicted for combination drug/device therapies. Representatives of venture capital firms and investment banks also attended the meeting to gather information on potential partnering opportunities.

Presenting companies included Light Sciences Corp., which discussed its progress on the development of its Litx System for the treatment of age-related macular degeneration and other diseases.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2024 MJH Life Sciences

All rights reserved.